Characterization of CAR T Cells Manufactured Using Genetically Engineered Artificial Antigen Presenting Cells.

ABSTRACT:

Objective

Chimeric antigen receptor (CAR) T cell therapy has recently emerged as a promising approach for the treatment of different types of cancer. Improving CAR T cell manufacturing in terms of costs and product quality is an important concern for expanding the accessibility of this therapy. One proposed strategy for improving T cell expansion is to use genetically engineered artificial antigen presenting cells (aAPC) expressing a membrane-bound anti-CD3 for T cell activation. The aim of this study was to characterize CAR T cells generated using this aAPC-mediated approach in terms of expansion efficiency, immunophenotype, and cytotoxicity.

Materials and methods

In this experimental study, we generated an aAPC line by engineering K562 cells to express a membrane-bound ant

SUBMITTER: Sayadmanesh A 

PROVIDER: S-EPMC10591261 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature